Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2696-2701

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Y.
Right arrow Articles by Schneider, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Y.
Right arrow Articles by Schneider, D. J.
Related Collections
Right arrow Pathophysiology
Right arrow Fibrinolysis
Right arrow Type 1 diabetes
Right arrow Type 2 diabetes
Right arrow Coagulation and fibronolysis
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2696.)
© 2000 American Heart Association, Inc.


Thrombosis

Identification and Localization of a Fatty Acid Response Region in the Human Plasminogen Activator Inhibitor-1 Gene

YaBing Chen; Joseph J. Billadello; David J. Schneider

From the Department of Medicine (Y.C., D.J.S.), The University of Vermont (Burlington); and Department of Medicine (J.J.B.), Washington University, St Louis, Mo.

Correspondence to David J. Schneider, MD, College of Medicine, University of Vermont, 208 South Park Dr, Suite 2, Colchester, VT 05446. E-mail djschnei{at}zoo.uvm.edu

Abstract—The increased expression of plasminogen activator inhibitor type-1 (PAI-1) is associated with increased concentrations of fatty acids in blood and may accelerate atherogenesis in diabetes. The present study was designed to define mechanisms by which nonesterified (free) fatty acids (FFAs) augment the expression of PAI-1. FFAs increased PAI-1 protein and mRNA expression by HepG2 cells. To identify potential regulatory elements, we constructed chimeric genes by fusing 1313, 853, 610, or 328 bp of human PAI-1 5'-flanking DNA to a luciferase reporter (PAI-LUC). A 2-fold increase in luciferase activity was seen when cells were transfected with PAI-LUC 1313, 863, or 610 and exposed to FFAs. No response to FFAs was seen with PAI-LUC 328 and after deletion of a 72-bp (-599 to -528) fragment from PAI-LUC 1313. This 72-bp fragment conferred FFA responsiveness to a different (simian virus 40) promoter. Two footprinted regions were demonstrated by DNase I analysis. Gel mobility shift assays indicated specific binding of extracted proteins to an FFA response element: 5'-TG(G/C)1–2CTG-3'. This sequence is repeated 4 times and is similar to an Sp1-binding site. Sp1 consensus oligonucleotides inhibited binding of extracted proteins to the regulatory elements. Accordingly, FFA-induced increased expression of PAI-1 in HepG2 cells is mediated by the binding of a transcription factor or factors to the repeated fatty acid response element, 5'-TG(G/C)1–2CTG-3', that is highly homologous to an Sp1-binding site.


Key Words: Diabetes mellitus • PAI-1 • free fatty acids • Sp1




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. H. Byon, A. Javed, Q. Dai, J. C. Kappes, T. L. Clemens, V. M. Darley-Usmar, J. M. McDonald, and Y. Chen
Oxidative Stress Induces Vascular Calcification through Modulation of the Osteogenic Transcription Factor Runx2 by AKT Signaling
J. Biol. Chem., May 30, 2008; 283(22): 15319 - 15327.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
A. M. Kanaya, C. Wassel Fyr, E. Vittinghoff, T. B. Harris, S. W. Park, B. H. Goodpaster, F. Tylavsky, and S. R. Cummings
Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.
Arch Intern Med, February 13, 2006; 166(3): 350 - 356.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Dong, S. Fujii, H. Li, H. Nakabayashi, M. Sakai, S. Nishi, D. Goto, T. Furumoto, S. Imagawa, T. A.K.M. Zaman, et al.
Interleukin-6 and Mevastatin Regulate Plasminogen Activator Inhibitor-1 Through CCAAT/Enhancer-Binding Protein-{delta}
Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 1078 - 1084.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H.-C. Chen and E. P. Feener
MEK1,2 response element mediates angiotensin II--stimulated plasminogen activator inhibitor-1 promoter activation
Blood, April 1, 2004; 103(7): 2636 - 2644.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
K. E. Watson, A. L. Peters Harmel, and G. Matson
Atherosclerosis in Type 2 Diabetes Mellitus: The Role of Insulin Resistance
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 253 - 260.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. E. Sobel, D. J. Taatjes, and D. J. Schneider
Intramural Plasminogen Activator Inhibitor Type-1 and Coronary Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 1979 - 1989.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M.-C. Alessi, D. Bastelica, A. Mavri, P. Morange, B. Berthet, M. Grino, and I. Juhan-Vague
Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation
Arterioscler. Thromb. Vasc. Biol., July 1, 2003; 23(7): 1262 - 1268.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
W. T. Cefalu, D. J. Schneider, H. E. Carlson, P. Migdal, L. Gan Lim, M. P. Izon, A. Kapoor, A. Bell-Farrow, J. G. Terry, and B. E. Sobel
Effect of Combination Glipizide GITS/Metformin on Fibrinolytic and Metabolic Parameters in Poorly Controlled Type 2 Diabetic Subjects
Diabetes Care, December 1, 2002; 25(12): 2123 - 2128.
[Abstract] [Full Text] [PDF]